



## Evaluation Report for Category B, Subcategory 3.10 Application

**Application Number:** 2023-1139  
**Application:** Category B.3.10 (New or Changes to the Product Label – Tank Mixes)  
**Product:** Miravis Neo 300 SE  
**Registration Number:** 33391  
**Active ingredient(s) (a.i.):** Azoxystrobin, Pydiflumetofen and Propiconazole  
**PMRA Document Number :** 3472244

### Background

Miravis Neo 300 SE (Reg. No. 33391; registered by Syngenta Canada Inc.) is a suspension commercial fungicide containing 100 g/L azoxystrobin, 75 g/L pydiflumetofen and 125 g/L propiconazole.

### Purpose of Application

The purpose of the subject application is to add the general tank mixing statement to the product label.

### Chemistry, Health and Environmental Assessment

Chemistry, health, and environmental assessments were not required as there was no change to product chemistry, product formulation, or use pattern.

### Value Assessment

A thorough review of the label determined that the addition of the general tank mixing statement is acceptable as it is consistent with the requirements in the PMRA Guidance Document – Tank Mix Labelling (March 16, 2023).

The inclusion of the general tank mixing statement on the label allows growers greater flexibility to select tank mixtures to control pests in labelled crops. Flexibility in the selection of tank mix partners may contribute to resistance management practices, integrated pest management programs or the control of a broader range of pests, with an associated cost- and time-savings by the user.

### Conclusion

The Pest Management Regulatory Agency has completed an assessment of the subject application and has found the inclusion of the general tank mixing statement to be acceptable on the product label.

## **References**

None

**© His Majesty the King in Right of Canada, as represented by the Minister of Health Canada, 2023**

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in a retrieval system, without prior written permission of Health Canada, Ottawa, Ontario K1A 0K9.